AI-driven atrial fibrillation project begins after seed funding roundClinical development of an AI-driven system that identifies the sources or drivers of atrial fibrillation (AF), and could Share XAI-driven atrial fibrillation project begins after seed funding roundhttps://pharmaphorum.com/news/ai-driven-atrial-fibrillation-project-begins-after-seed-funding-round/
Heart failure results could unlock key market for Farxiga – AZAstraZeneca doesn’t quite know why its diabetes drug Farxiga is also working in patients with heart failure – Share XHeart failure results could unlock key market for Farxiga – AZhttps://pharmaphorum.com/news/heart-failure-results-could-unlock-key-market-for-farxiga-az/
FDA fast-tracks AZ’s Farxiga in potential new CKD indicationThe FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and Share XFDA fast-tracks AZ’s Farxiga in potential new CKD indicationhttps://pharmaphorum.com/news/fda-fast-tracks-azs-farxiga-in-potential-new-ckd-indication/
AliveCor stops selling ECG wristband for Apple Watches – reportMobile ECG maker AliveCor has stopped sales of its FDA-approved ECG wristband for use with Apple Watches, according Share XAliveCor stops selling ECG wristband for Apple Watches – reporthttps://pharmaphorum.com/news/alivecor-stops-selling-ecg-wristband-for-apple-watches-report/
AZ’s Farxiga first in class to improve outcomes in heart failureAstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class Share XAZ’s Farxiga first in class to improve outcomes in heart failurehttps://pharmaphorum.com/news/azs-farxiga-first-in-class-to-improve-outcomes-in-heart-failure/
Regeneron preps for 2020 filing for new cholesterol drug after trial successRegeneron has announced data that could create a niche for its latest cholesterol drug evinacumab in a small Share XRegeneron preps for 2020 filing for new cholesterol drug after trial successhttps://pharmaphorum.com/news/evinacumab-regeneron-cholesterol-drug-trial/
NICE backs Bayer’s Xarelto in new stroke and heart attack prevention useBayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults Share XNICE backs Bayer’s Xarelto in new stroke and heart attack prevention usehttps://pharmaphorum.com/news/nice-backs-bayers-xarelto-in-new-stroke-and-heart-attack-prevention-use/
Novartis’ heart failure drug misses expanded use trial targetNovartis has announced that its heart failure drug Entresto has failed in a trial that the company hoped Share XNovartis’ heart failure drug misses expanded use trial targethttps://pharmaphorum.com/news/novartis-heart-failure-drug-misses-expanded-use-trial-target/
Yale, Mayo and FDA experts aim to rethink heart failure trials with Apple WatchA group of scientists from Yale University and the Mayo Clinic are to use an Apple Watch app Share XYale, Mayo and FDA experts aim to rethink heart failure trials with Apple Watchhttps://pharmaphorum.com/news/yale-mayo-and-fda-experts-aim-to-rethink-heart-failure-trials-with-apple-watch/
